fashion -WSS

fashion

author：focus 2025-09-28 21:06:18 - browse：7

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： For Cytokinetics, FDA rejection of heart drug would help, not hinder

focus

WSS

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

California wildfire smoke linked to 52,000 early deaths, study says

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

FDA panel issues narrow recommendation for Covid vaccine booster doses

focus

fashion

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Duchenne breakthrough therapy leaves behind pioneering families

Report captures long Covid’s disabling effects and policy challenges

Peter Hotez and the public health issue of online harassment

For Cytokinetics, FDA rejection of heart drug would help, not hinder

What does generative AI mean for health care? We asked experts

Curing rare childhood diseases will falter unless Congress steps up

Psychedelics group wrestles with new pharma identity

The system is set up to fail children with medical complexity

entertainment

Maui's cultural, historic landmarks damaged in the devastating wildfires

NIH tests clinical research in primary care with $30 million program

South Korea throws huge K

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Drastic changes should bring profitability, startup health insurers say

How faith leaders like me can help address America's obesity epidemic

Wikipedia

focus

focus

explore